GlobeNewsWire
26 Nov 2025, 21:01 UTC · 45w ago
Impact · against what's priced in
Pacira BioSciences extends its monopoly on EXPAREL by triggering a 30-month FDA stay on generic versions through patent litigation. This provides a guaranteed window of protection and reinforces the long-term valuation of its core revenue driver.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Pacira BioSciences filed patent infringement lawsuits against The WhiteOak Group and Qilu Pharmaceutical regarding EXPAREL.
More positive than 78% of claims this week
The lawsuits triggered an automatic 30-month stay of final FDA approval for the generic versions of EXPAREL under the Hatch Waxman Act.
Continue reading
5 related stories
The filing of lawsuits against The WhiteOak Group and Qilu Pharmaceutical secures a 30-month stay on generic FDA approval, delaying competition for EXPAREL while asserting patent protections that extend into 2041 and 2044.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 65% of claims this week
Pacira's EXPAREL patent protections extend through January 2041 and July 2044.
So whatLong-dated patent horizons provide long-term valuation support and predictability for cash flows.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
The company is aggressively defending its intellectual property and successfully triggered a 30-month stay on generic competition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
9h ago
+52.5%
Price agrees with the score
$36.30 vs $23.81 close before publication (Nov 26) · not market-adjusted
PCRX chart →
